A Word Visualization Observation: The Hidden Meaning of the Words in Work Environments

The aim of this study is to illustrate and semantically explain how the visualization of words is helpful to create word trees, showing the connection between various, synonym words and to explore the hidden meanings behind each word in the tree, particularly to provide a true message in work environments. To do this, the authors have chosen one main word “lying” and two connected, synonymous words to it “fabrication” and “prevarication”. The words have been chosen spontaneously, by considering their employment in communications, particularly in work environments. To uncover the variety and implication of these words the study is divided into two sections: a short secondary data collection and an observational part. The short literature review accomplished by a secondary data collection highlights the importance of word visualization through different methods and tools through communications in, particularly, workplaces. And the observations in the methodology bring complimentary proof after the secondary data collection. With the use of word visualizations such as mind maps and word clouds, this study illustrates the further importance of word visualizations which opens new perspectives upon other words for diverse studies and fields as seen in the glossary, a dictionary of the words, employed in Picture 1 which is provided as an example of source presentation for future works in similar studies.

The Rev II Trial: Lenalidomide and Dexamethasone As Second Line Treatment in Myeloma Followed By Extended Lenalidomid Vs Len/Dex

Background The indication for use of lenalidomide in second line of therapy has been based upon two phase III studies comparing lenalidomide and dexamethasone vs. placebo and dexamethasone (Weber 2007, Dimopoulos 2007) showing a TTP of 11.1 and 11.3 months respectively. In 2009 Stadtmauer et al showed that patients with only one prior therapy had significantly longer median TTP compared with those treated in later lines (17.1 months vs. 10.6 months). Here we report outcomes from the REVII trial in 2nd line treatment of MM, a two part study with first an observational part with standard treatment of lenalidomide combined with corticosteroids and then, a randomized part, where patients that had responded in the first part, were randomized to lenalidomide combined with dexamethasone or lenalidomide as a single drug. Methods 132 patients with multiple myeloma in first relapse were included in the first, observational part of the study, and treated with up to 9 cycles of lenalidomide combined with betamethasone or dexamethasone according to local routines. Patients that had achieved at least partial response and had consolidation treatment with at least two additional cycles were offered to take part in the second part of the study. In the second part 63 patients were randomized to be treated with either lenalidomide combined with dexamethasone (LenDex) or lenalidomide as a single drug (Len) for a maximum of 24 cycles. In the first part of the study the primary endpoint was time to response and secondary endpoints were quality of life, safety and cytogenetic markers as gain 1q21, t(4;14), t(11;14) and del17p. In the second part, primary endpoint was time to progression and secondary endpoint was safety. In the second part we also performed detailed NK/T-cells phenotype analyses. Survival data were calculated from first entry in the observational study. Data cutoff was 1st of July 2015, with a median follow-up of 21.4 months. Results A very high proportion of patients achieved PR or better (≥PR 84%). Of the patients 3% were primary refractory and 12% achieved a minor response or stable disease. Very good partial response or better (≥VGPR) was achieved in 44% of the patients. First response, at least PR, was achieved after a median of 7 weeks and best response after a median of 10 weeks. After randomizations no differences in responses between the Len and the LenDex group were found. Late responses were common and 7 of the patients received their best response after more than one year of treatment. Median overall survival (OS) was not reached. 61% of the participants were still alive at the data cut off. OS in the first part was 32 months and 78% of the patients in the second part were still alive at data cut off. Median time to progression (TTP) for the whole study was 16 months and for the first and second part 10 and 30 months respectively. After randomization TTP in the Len-group was 25 months and in the LenDex median TTP was not reached, 54% of the participants were still alive after 36 months of treatment. The difference between the two groups was not significant (p=0,48). Patients with gain1q21 had median OS of 31 months while 77% of patients with no gain 1q21 where still alive at the same time (p=0.054). TTP for patients with or without gain of 1q21 was 11 months vs. 28 months respectively (p=0.014). Patients with either gain 1q21, t(4;14) and/or del17p had a TTP of 11 months while patients with none of these chromosomal aberrations had a TTP of 30 months (p=0.0058). NK/T-cells phenotype data will be presented at the congress. Discussion Len/Dex was associated with a very high response rate at 2nd line treatment of MM. On achieving at least PR, continuing with dexamethasone in addition to len does not add any benefit for the patients regarding responses, TTP or OS. As expected, chromosomal abnormalities had a negative impact on TTP and OS. Disclosures Waage: Celgene: Research Funding; Janssen: Research Funding; Amgen: Research Funding. Gimsing:Amgen: Honoraria. Mellqvist:Celgene, Amgen, Mundipharma and Novartis: Honoraria. Nahi:Celgene: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau.

Determination of the Gravitational Potential of Seyfert Cores from High-Resolution Spatial and Spectral Data

We summarize the current state of our project to determine the gravitational potential in the innermost few hundred parsecs of Seyfert cores from observed line-of-sight velocities of molecular clouds. Therefore we distinguish between the observational part on the one hand and the theoretical aspects on the other. On the theoretical side the problem is lack of knowledge of the flow pattern and the spatial distribution of the clouds. We analyze the possibility of distinguishing between the different flow patterns and determining the mass distribution. On the observational side the problem is obtaining sufficiently high spatial and spectral resolution.

New Measurements of Positions for the Astrographic Catalogue Stars

Six observatories of the former USSR carry out photographic observations within the FON project (the fourfold coverage of the northern sky) since 1982. The same type wide-angle Zeiss astrographs (D=400 mm, F=2000 and 3000 mm) are used. At present Golosiiv Observatory almost finished the Kiev observational part of the project and the measurements of onefold coverage plates have been started. The special measuring machine PARSEC (Programming Automatic Radial-Scanning Coordinatometer) has recently been constructed for this purpose.We intend to apply the measurements of the FON project plates to the determination of new positions and proper motions of all stars in the Astrographic Catalogue (AC) using the last one as the first epoch of observations. AC is applied also as input catalogue for PARSEC. About 500 plates have been measured at the moment and proper motions for more than 500000 stars in different areas of the northern sky have been obtained.The accuracy of the FON positions and proper motions of stars from the measurements of onefold coverage plates is estimated to be 0.35 arcsec and 0.006 arcsec/yr, respectively.Futher investigations will be carried out in cooperation with Sternberg Astronomical Institute (Moscow, Russia) and Astronomisches Rechen-Institut (Heidelberg, Germany).The above-described reasearches became possible partly by Grant N V41000 from the International Science Foundation.

Analysis of Intensity Ratio for MgXII Lyα Components from Intercosmos 7 Observations

We discuss the Mg XII Lyα line profile measurements obtained, by means of Bragg crystal spectrometer aboard INTERCOSMOS 7 satellite. The design of this spectrometer allows to clearly resolve both components α½ and α3/2) of the Lyα spin doublet. The intensities of each of these components we derived by means of fitting two Voigt profiles to the measured Mg XII Lyα shape. More than 100 spectra were analyzed in this way providing the statistical information on the value of intensity ratio . Derived average value of a is close to the theoretically expected 0.5, but in many cases the value of a is significantly different from 0.5 (both lower and higher values occur). We present examples of the fit and the histograms showing correlations of a value with the values of other flare parameters. Present analysis consist the observational part of the larger paper under the preparation with Prof. R.W.P. McWhirter theoretical group.